Now the DEA is trying to crush cannabis research
The poor quality of research-grade marijuana is skewing the results of cannabis research, according to a report released earlier this year by the National Academies of Sciences, Engineering and Medicine (NASEM). “Because of restrictions on production and vicissitudes in supply and demand, federally produced cannabis may have been harvested years earlier, is stored in a freezer (a process that may affect the quality of the product), and often has a lower potency than cannabis sold in state-regulated markets,” NASEM wrote in the report.
So thanks to the DEA, cannabis researchers are facing an even lower supply of an inferior product, and they have nowhere else to turn. But as bad as things are for them, the situation is even more grim for patients who might benefit from the breakthroughs in cannabis research that the federal government is obstructing. Marijuana is a potential treatment for many serious conditions from cancer to the opioid epidemic that is claiming over 30,000 American lives every year. That means the DEA isn’t just reducing the amount of marijuana grown for scientific study. By interfering with cannabis research, it is reducing the quality of life for millions of Americans.